A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Exclusion Criteria

• •9. Must have at least one measurable lesion according to RECIST v1.1 definition.
• •10. ECOG score 0 or 1.
• •11. Toxicity of previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 .
• •12. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%.
• •13. Organ function levels must meet the requirements.
• •14. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN.
• •15. Urine protein ≤2+ or ≤1000mg/24h.
• •16. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum/urine pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
• •1. Received chemotherapy, biological therapy, immunotherapy or other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs, etc.).
• •2. Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin.
• •3. Presence of other gene mutations for targeted drug therapy.
• •4. A history of severe cardiovascular and cerebrovascular diseases.
• •5. Active autoimmune or inflammatory diseases.
• •6. Patients with other malignant tumors within 5 years before the first administration.
• •7. Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded.
• •8. Patients with poorly controlled pericardial effusion, pleural effusion, peritoneal effusion, or pelvic effusion with clinical symptoms were judged by the investigator to be ineligible for enrollment.
• •9. Hypertension poorly controlled by antihypertensive drugs (systolic BP \> 150 mmHg or diastolic blood pressure \> 100 mmHg).
• •10. Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases.
• •11. Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastases). .
• •12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any ingredient of BL-M07D1.
• •13. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
• •14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \> lower detection limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \> lower detection limit).
• •15. Active infections requiring systemic therapy, such as severe pneumonia, bacteremia, sepsis, etc.
• •16. Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of the last dose).
• •17. Pregnant or lactating women.
• •18. Other circumstances considered by the investigator to be inappropriate for participation in the trial.